In fact, IGF-1R was the first RTK to be targeted by an inhibitory antibody in preclinical studies, when neutralizing antibody αIR3 was shown to inhibit growth of breast cancer cells in vitro and as xenografts in immunodeficient mice [111]. Here, IGF1R is linked to breast carcinoma.